Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection Images
Generic Name: ranibizumab
This medication has been identified as Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection. It is supplied by Coherus BioSciences, Inc.
Cimerli is used in the treatment of Macular Edema Following Retinal Vein Occlusion; Macular Degeneration; Myopic Choroidal Neovascularization; Macular Edema; Diabetic Macular Edema and belongs to the drug class anti-angiogenic ophthalmic agents. Risk cannot be ruled out during pregnancy. Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Cimerli
- Generic Name
- ranibizumab
- Strength
- 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection
- Availability
- Prescription only
- Drug Class
- Anti-angiogenic ophthalmic agents
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Coherus BioSciences, Inc.
- National Drug Code (NDC)
- 70114-0440
More about Cimerli (ranibizumab ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-angiogenic ophthalmic agents
- Breastfeeding
- En español
Patient resources
- Cimerli drug information
- Cimerli ophthalmic
- Cimerli (Ranibizumab Intraocular) (Advanced Reading)
- Cimerli (Ranibizumab-eqrn Intraocular) (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.